Drug Patent Watch
NOVEMBER 10, 2020
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find a solution that fits. If your colleagues would like to…. The post Thinking of signing your company up for DrugPatentWatch? appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
NOVEMBER 10, 2020
The German company BioNTech, founded by two scientists, has teamed up with Pfizer on a vaccine that was found to be more than 90 percent effective.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
NOVEMBER 12, 2020
A leader from the AI technology firm discusses how life-sciences pros are harnessing AI to help continue their work in the face of the pandemic.
pharmaphorum
NOVEMBER 11, 2020
Abid Rahman from Intouch Group tells pharmaphorum how AI-based technology is solving challenges across healthcare systems, pharmaceutical companies, and patient treatment. With AI already the key engine for a growing list of consumer devices, the trend has created exciting opportunities for pharma and healthcare. “We have now entered a new phase of AI implementation where AI-based technology is expected to be foundational and not just a novel technology,” Abid Rahman, vice president, innovation,
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
NOVEMBER 12, 2020
Interim data analysis comes from phase III clinical trials in the Russian Federation
NY Times
NOVEMBER 8, 2020
Researchers ended a clinical trial of the drug early because the results were so convincing. The more effective drug would be given in six injections a year instead of as 365 daily pills.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
NOVEMBER 11, 2020
In the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been shown to be 92% effective at the interim point of a 40,000-patient study. The preliminary assessment is based on 20 coronavirus cases split between the vaccinated and placebo arms of the study at 21 days, according to a press statement issued this morning by the Gamaleya Institute which developed the shot and the Russian Direct Investment Fund (RDIF).
Pharma Times
NOVEMBER 9, 2020
Phase III study of vaccine candidate involved 43,538 participants
NY Times
NOVEMBER 11, 2020
La compañía alemana BioNTech, fundada por dos científicos, se ha asociado con Pfizer en una vacuna cuya eficacia se ha comprobado en más de un 90 por ciento.
Outsourcing Pharma
NOVEMBER 10, 2020
The two companies have joined forces to collaborate on the commercial launch of Gimoti, a nasal spray for patients suffering from diabetic gastroparesis.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
NOVEMBER 11, 2020
In the first episode of our Health Innovators series, Paul Tunnah speaks to David Van Sickle, CEO of Propeller Health about how digital technologies are revolutionising the field of respiratory medicine. The post Health Innovators: David Van Sickle on digital innovation in respiratory medicine appeared first on.
Pharma Times
NOVEMBER 13, 2020
Agreement follows positive phase III data announcement
NY Times
NOVEMBER 9, 2020
What’s the big deal? Was it part of Operation Warp Speed? When can you get one?
Outsourcing Pharma
NOVEMBER 9, 2020
President-elect Joe Biden has launched a Transition COVID-19 Advisory Board to support the USâ COVID-19 response.
pharmaphorum
NOVEMBER 12, 2020
CatalYm has closed a €50 million ($59m) series B financing round to fund clinical studies of its immunotherapy targeting Growth Differentiation Factor 15 (GDF-15). The round was led by Vesalius Biocapital III, with participation from Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and founding investors Forbion and BioGeneration Ventures.
Pharma Times
NOVEMBER 10, 2020
Akcea’s Waylivra approved via ultra-orphan pathway
NY Times
NOVEMBER 9, 2020
The authorization raised immediate questions about who would get access to the antibody treatments, which are in short supply.
Outsourcing Pharma
NOVEMBER 10, 2020
Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
pharmaphorum
NOVEMBER 12, 2020
The European Union has ordered 300 million doses of BioNTech/Pfizer’s COVID-19 vaccine following this week’s landmark announcement that it was effective in more than 90% of patients. The companies said deliveries of an initial order of 200 million vaccines will be subject to approval by European regulators and are expected to start by the end of this year.
Pharma Times
NOVEMBER 11, 2020
Detailed results are due to be presented at forthcoming medical meeting
NY Times
NOVEMBER 13, 2020
A new study shows that more than half of enrollees don’t review or compare their coverage options annually.
Outsourcing Pharma
NOVEMBER 9, 2020
According to a survey by trial solutions company Greenphire, patient recruitment and enrollment levels have bounced back since the pandemic struck.
pharmaphorum
NOVEMBER 13, 2020
Since Covid-19 hit, many industries have shifted a heavier weighting of their business into the online world, relying on e-commerce and digital engagement to counterbalance the reduced ability for physical interactions. The pharma world is no exception, and this year both small and large players have made the transition – partly out of necessity – from a world that relied predominantly on the face-to-face side of doing business, into a new digital world.
Pharma Times
NOVEMBER 9, 2020
Industry bodies respond to Specialised Committee outcome
Drug Patent Watch
NOVEMBER 13, 2020
Annual Drug Patent Expirations for NEOPROFEN Neoprofen is a drug marketed by Recordati Rare and is included in one NDA. It is available from two suppliers. There are three patents…. The post New patent expiration for Recordati Rare drug NEOPROFEN appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
NOVEMBER 13, 2020
On November 12, 2020, The Pharma CX Tech Summit held their third annual conference. The topics focused on the emerging technologies that pharma is implementing to enhance customer experiences for patients, payers, and HCPs. These technologies include AI/ML, voice & chat, connected devices, AR/VR, automation, personalization, and telehealth. . During the summit, speakers shared their thoughts and opinions on new technologies, how to prioritize customer experiences during COVID-19, and their
pharmaphorum
NOVEMBER 9, 2020
The FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors have little doubt that the evidence for the drug is lacking. The much-anticipated advisory committee meeting held on Friday to discuss the marketing application for aducanumab proved to be a fractious affair, with both the companies’ data – and some of the FDA’s interpretation of it – under fire by panellists.
Pharma Times
NOVEMBER 10, 2020
RECOVERY study will assess if drug can reduce risk of blood clots
Drug Patent Watch
NOVEMBER 13, 2020
Annual Drug Patent Expirations for STEGLUJAN Steglujan is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Merck Sharp drug STEGLUJAN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
NOVEMBER 13, 2020
Today’s guest post comes from Anndi McAfee, a successful voice over artist. Check out her impressive IMDB credits. Your kids have definitely heard her voice. Anndi also suffers from a rare disease and requires treatment with an orphan drug. Below, she shares her troubling experiences with SaveonSP, the mysterious company behind Express Scripts’ copay maximizer program.
pharmaphorum
NOVEMBER 9, 2020
As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim analysis. The companies said they will be ready to file the vaccine with the FDA in the third week of November once they have enough safety data to meet the regulator’s requirements.
Pharma Times
NOVEMBER 9, 2020
Conclusions made by a group of experts from academia and industry
Drug Patent Watch
NOVEMBER 12, 2020
Annual Drug Patent Expirations for ELIGARD+KIT Eligard Kit is a drug marketed by Tolmar Therap and is included in four NDAs. It is available from one supplier. There are five…. The post New patent expiration for Tolmar Therap drug ELIGARD KIT appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
NOVEMBER 12, 2020
Healthcare Internet Conference ( HCIC) | November 16-19, 2020 | VIRTUAL. Greystone.Net’s annual Healthcare Internet Conference (HCIC) is the premier conference for healthcare marketing, IT, web, data analytics, business development, public relations and communication leaders who are responsible for their organization’s public-facing websites, intranets, portals, social channels, mobile strategy and CRM strategies.
pharmaphorum
NOVEMBER 13, 2020
US data analysis company Palantir Technologies could be drafted in to manage the UK government’s troubled COVID-19 Test and Trace programme, according to press reports. Palantir has been linked with the project for several weeks and the Financial Times is the latest to suggest that the company could get involved with the troubled project. Palantir was founded in 2003 by a team including paypal co-founder Peter Thiel and the company’s billionaire CEO Alex Karp.
Expert insights. Personalized for you.
134 
Let's personalize your content